≥99% Purity Verified by Third-Party Labs
    Free Shipping on Orders Over $100
    HPLC & Mass Spec 2X Tested
    Same Day Shipping on Orders Before 2PM EST Mon-Sat
    ≥99% Purity Verified by Third-Party Labs
    Free Shipping on Orders Over $100
    HPLC & Mass Spec 2X Tested
    Same Day Shipping on Orders Before 2PM EST Mon-Sat

    Research use only · Not for human or veterinary use

    α
    ALPHA CARBON LABS
    Best Seller
    Cagrilintide + Semaglutide Blend research peptide - high purity lyophilized powder for laboratory research

    10mg (5mg/5mg)

    $125
    3ml Vial
    In Stock
    Bulk Discounts

    Buy 3+ for $118.75 each and save 5%

    Buy 5+ for $112.50 each and save 10%

    Buy 10+ for $106.25 each and save 15%

    This product is for research purposes only. Not for human consumption.

    Purity: >98% (HPLC verified)

    Formulation: Lyophilized powder blend

    Molecular Formula: C171H265N45O53S2 + C187H291N45O59

    Molecular Weight: 3912.4 + 4113.64 g/mol

    CAS Number: N/A / 910463-68-2

    PubChem CID: N/A / 56843331

    Cagrilintide + Semaglutide Blend

    GLP-1 Agonists

    Overview

    This material is provided for controlled laboratory research and analytical characterization only.

    Mechanism of Action

    Refer to the cited literature for research concerning this material's molecular characteristics and experimental targets.

    Research Findings

    Published nonclinical literature relevant to this material's molecular targets and experimental models is listed below for independent review. Findings involving other preparations or experimental systems should not be attributed to this research material.

    Research Applications

    • Amylin and GLP-1 receptor signaling studies
    • Gastric emptying and postprandial glucose research
    • Combination peptide pharmacology studies
    • Energy intake and food reward research
    • Comparative metabolic peptide studies

    Laboratory Handling & Limitations

    This material is supplied solely for in vitro and other nonclinical laboratory research. It is not for human or veterinary use, consumption, administration, therapeutic use, or diagnostic use.

    Laboratory Handling

    Handle only in an appropriately equipped laboratory using applicable institutional procedures, personal protective equipment, and the storage conditions shown for the material. The purchaser is responsible for study design, handling controls, disposal, and regulatory compliance.

    Research Limitations

    Published observations involving other preparations, experimental systems, or study populations do not establish the identity, performance, or suitability of this research material for any particular experiment.

    Scientific References

    1. Enebo, L. B., et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. The Lancet, 397(10286), 1736-1748.
    2. Frias, J. P., et al. (2023). Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. The Lancet, 402(10403), 720-730.
    3. Lau, D. C. W., et al. (2021). Once-Weekly Cagrilintide for Weight Management in People with Overweight and Obesity: A Multicentre, Randomised, Double-Blind, Placebo-Controlled and Active-Controlled, Dose-Finding Phase 2 Trial. The Lancet, 398(10317), 2160-2172.
    4. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002.
    5. Boyle, C. N., et al. (2022). Amylin and GLP-1 combination therapy: a new frontier in obesity treatment. Trends in Endocrinology & Metabolism, 33(8), 537-549.

    Research Use Only

    This product is intended for research purposes only and is not for human consumption, therapeutic use, or diagnostic applications. Please ensure compliance with all applicable regulations and institutional guidelines.